Pulmonary Hypertension
Articles tagged with Pulmonary Hypertension
Results of major heart study set to save lives, reduce unneeded heart implants
Taking pressure off the lungs
Researchers at Kyoto University have discovered that targeting the CNP/GC-B signal pathway may provide a promising approach for treating Pulmonary Arterial Hypertension (PAH). The study reveals that CNP/GC-B signaling plays a protective role against PAH, and administration of CNP ameliorates experimental pulmonary hypertension.
Prenatal and early-life pollution exposures may influence childhood blood pressure patterns, ECHO study finds
A new study from the ECHO Program found that exposure to fine particulate matter (PM2.5) and nitrogen dioxide (NO2) before and after birth may influence childhood blood pressure patterns. High blood pressure in children is a growing concern worldwide, with nearly 80% increase over two decades.
Baveno VII guidelines: shaping the future of portal hypertension management
The Baveno VII consensus guidelines have reshaped portal hypertension management, focusing on early intervention and noninvasive diagnostics. Nonselective beta-blockers and transjugular intrahepatic portosystemic shunt (TIPS) are recommended for clinically significant portal hypertension diagnosis.
Biologic drug reduces symptoms, hospitalization for severe pulmonary hypertension after diagnosis
A phase 3 clinical trial found that sotatercept significantly reduces the likelihood of worsening disease in patients with severe pulmonary hypertension when added to standard treatment within the first year after diagnosis. The medication reduced the risk of deterioration by 76% and hospitalizations by nearly half.
Distinguished physician-scientist and nationally recognized pulmonologist Roberto Machado, MD, named Chair of the Department of Medicine at the University of Maryland School of Medicine
Dr. Machado brings scientific expertise, clinical leadership, and mentorship to the Department of Medicine at UMSOM. He will advance research impact, enhance clinical excellence, and shape the future of academic medicine.
Improved prognosis for chronic thromboembolic pulmonary hypertension over recent decades
Recent studies have revealed significant improvements in patient prognosis for chronic thromboembolic pulmonary hypertension (CTEPH) over the past few decades. Advances in surgical techniques, drug development, and multimodal therapies have led to increased treatment rates and improved survival rates among patients.
New technology developed at the Lewis Katz School of Medicine at Temple University promises faster, earlier diagnosis of deadly form of heart failure
A novel screening approach called VEST uses virtual echocardiography to identify patients at high risk of pulmonary arterial hypertension, a life-threatening form of heart failure. The tool has been shown to generate accurate PAH risk scores without manual calculations and can guide timely referrals for expert care.
New pulmonary arterial hypertension treatment offers hope for patients in advanced stage of disease
Researchers found a 76% lower risk of death in advanced pulmonary arterial hypertension patients treated with sotatercept. The therapy significantly reduced hospitalization rates and improved patient outcomes.
Largest phase 3 trial of novel treatment for hypertension shows promising results
A phase 3 trial announced today demonstrated lorundrostat's safety and effectiveness in reducing blood pressure in patients with resistant hypertension. The treatment, which blocks the production of aldosterone from the adrenal glands, achieved clinically meaningful and sustained reductions in systolic blood pressure.
Maternal cardiometabolic health during pregnancy associated with higher blood pressure in children, NIH study finds
A new NIH study found that maternal cardiometabolic health before and during pregnancy is associated with higher blood pressure in children. The study analyzed data from 12,480 mother-child pairs and identified three key risk factors: pre-pregnancy obesity, gestational diabetes, and high blood pressure during pregnancy.
Novel rat model paves the way to advance COPD-associated cor pulmonale research
Researchers developed a novel rat model that closely replicates human COPD-associated cor pulmonale, exhibiting chronic lung inflammation, pulmonary hypertension, and right ventricular hypertrophy. The model provides insights into the underlying mechanisms of disease progression and potential therapeutic targets.
Day-long conference addresses difficult to diagnose lung disease
A day-long conference brought together experts to present ground-breaking outcomes research on CTEPH treatments. The session covered new medications, refined techniques, and innovative approaches to improve diagnosis and treatment outcomes.
Commonly prescribed medications for high blood pressure have unexpected side effects
Researchers at Penn's School of Dental Medicine and Perelman School of Medicine found that ACE inhibitors can inhibit the activity of ACE2, a critical cardioprotective enzyme. This discovery has implications for human patients prescribed these medications, who may benefit from additional ACE2 treatment.
Breakthrough research revolutionizing pulmonary hypertension treatment
A recent study published in the International Journal of Cardiology analyzed data from multiple clinical trials to assess the therapeutic impact of pulmonary artery denervation (PADN) on pulmonary hypertension patients. PADN showed significant reductions in mean right atrial pressure, mean pulmonary artery pressure, and pulmonary vascu...
ACC to host Cardio-oncology Conference in Washington and virtually
The ACC Advancing the Cardiovascular Care of the Oncology Patient conference will provide clinicians with tools to improve cardiovascular care of cancer patients. Key sessions will include discussions on pulmonary tumor thrombotic microangiopathy, AI and technology in cardio-oncology.
Five minutes of exercise a day could lower blood pressure
A new study suggests that adding physical activity into daily life can help lower blood pressure. Replacing sedentary behaviors with 20-27 minutes of exercise per day was estimated to lead to a clinically meaningful reduction in blood pressure, while just five minutes of activity a day was also associated with reduced levels.
Effects of transjugular intrahepatic portosystemic shunt on renal and pulmonary function in hepatic decompensation with and without hepatorenal and hepatopulmonary syndromes
The TIPS procedure improves renal function in patients with portal hypertension, particularly those with refractory ascites. However, the benefits of TIPS for Hepatorenal Syndrome (HRS) and Hepatopulmonary Syndrome (HPS) are limited due to insufficient data.
Active plant substance reduces pulmonary hypertension
Researchers found that a compound from the Ardisia crenat houseplant inhibits Gq proteins, which can help relax pulmonary vessels and alleviate symptoms of pulmonary hypertension. The study showed significant vascular relaxation in mice with pulmonary hypertension, improving their health condition.
Hormone Replacement Therapy (HRT) may improve pulmonary hypertension and right ventricular function
A recent study found that hormone replacement therapy (HRT) was associated with improved pulmonary hypertension and right ventricular function in women. The researchers analyzed data from over 700 women with pulmonary hypertension and found that those who used HRT had lower mean pulmonary artery pressure and higher right ventricular fr...
New treatment strategies for a rare, potentially fatal, lung disease
Researchers discovered that IL-6 signaling in CD4-positive T cells promotes pulmonary hypertension development and progression. Treating mice with IL-6 inhibitors improved symptoms and decreased damage to the lungs and heart.
Dietary changes may treat pulmonary hypertension
Scientists at University of Pittsburgh show that limiting glutamine and serine intake can halt disease progression in rodent models. The findings suggest a potential new therapy for patients with pulmonary hypertension, offering hope for improved treatment options beyond medications.
UMSOM researchers identify safety of a potential new treatment to manage complications from sickle cell disease
Researchers found that riociguat significantly improved blood pressure and reduced the risk of serious adverse events compared to a placebo treatment. The study showed promising results for this potential new treatment to manage complications from sickle cell disease, paving the way for larger clinical trials.
Almodóvar receives NIH grant to study pulmonary hypertension in HIV patients
The Almodóvar lab is studying the link between HIV and pulmonary hypertension, a condition that increases pressure in lung arteries. By examining the interactions between different cell types and using a humanized mouse model, researchers hope to propose novel therapies to prevent lung diseases in people with HIV.
First therapeutic target for preserving heart function in patients with pulmonary hypertension
A study published in Science Advances identifies a mitochondrial protein called MCJ as the first therapeutic target to preserve cardiac function in pulmonary hypertension. Modulating MCJ levels can activate a signaling pathway essential for adaptation to low oxygen levels, protecting the heart.
Genetics may influence the body’s response to low oxygen, Pitt study finds
Researchers found a shared genetic trait that predicts a higher risk of small lung vessel disease and its severe form, pulmonary arterial hypertension. This discovery could lead to personalized treatments for patients with limited oxygen response.
Major breakthrough in hypertension diagnosis could save Government billions
Researchers have discovered a way to predict which individuals will respond to blood pressure treatments that lower sodium in the body. This breakthrough could lead to a 25% reduction in hypertension prevalence, resulting in significant cost savings for the Australian government.
New target identified for pulmonary hypertension treatment
Researchers have identified a new therapeutic target for pulmonary hypertension treatment by discovering an epigenetic pathway mediated via the protein SPHK2 that can reduce and potentially reverse vascular remodeling. This discovery offers new hope for treating pulmonary hypertension, which is a complex and often fatal condition.
Why are Black adults at greater risk of death from heart disease? Study blames social factors
A new study from Tulane University found that Black adults are 54% more likely to die of cardiovascular disease than White Americans, largely due to social factors. The study's lead author suggests that addressing unemployment, low income, and lack of a partner can help reduce this disparity.
EMBARGOED: Mount Sinai Pulmonologists to Present New Research on Asthma and Sleep Disorders at ATS 2023 International Conference
Researchers from Mount Sinai Health System will present studies on pediatric pulmonary vascular disease, asthma, and sleep disorders. The findings focus on prevalence of pulmonary hypertension in children with severe obstructive sleep apnea and associations between diet and lung function decline.
Chronic thromboembolic pulmonary vascular disease and left heart disease are not mutually exclusive
A long-term analysis reveals that approximately one-third of CTEPH patients also have left heart disease, which can worsen breathing symptoms and requires more comprehensive diagnostic approaches. The study suggests that treatment options for both conditions may overlap, necessitating further research to find effective therapies.
Balloon pulmonary angioplasty, a novel treatment for chronic blood clots in lung arteries, gives patients a new lease on life, Lewis Katz School of Medicine at Temple University study shows
A novel treatment approach called balloon pulmonary angioplasty has been shown to be effective in treating chronic blood clots in lung arteries. The procedure improves exercise capacity and quality of life, with some patients able to stop medications altogether. Refinements in technique have improved the procedure's safety and efficacy.
Complications for procedure to open clogged pulmonary arteries decrease significantly
Researchers found decreased lung injury, coughing up blood, and mortality rates after balloon pulmonary angioplasty between 2013 and 2022. The minimally invasive procedure is now considered a safer option for inoperable CTEPH patients.
Gene essential to making DNA appears to be a good target in minimizing pulmonary hypertension
Researchers discover that inhibiting a gene crucial for DNA production can significantly reduce destructive cell proliferation and disease progression in pulmonary hypertension. This finding presents a potential treatment target for the condition, which affects females aged 30-60 with limited treatment options.
This groundbreaking biomaterial heals tissues from the inside out
A new biomaterial has been developed that can be injected intravenously to promote cell and tissue repair, reducing inflammation in damaged tissues. The material has shown promising results in treating heart attacks and traumatic brain injury in animal models.
Novel blood test helps evaluate severity in pulmonary arterial hypertension, a rare lung disease
Researchers developed a novel blood test that measures cell-free DNA to evaluate PAH severity and predict survivability. The test showed significant improvement over conventional tests and may allow doctors to intervene faster to prevent disease progression.
New research shows that women with pulmonary hypertension have chance at safe pregnancy thanks to advanced cross-specialty care at Temple University hospital
Researchers at Temple University hospital found that maternal-fetal mortality can be reduced to zero through patient-tailored management of right heart function prior to delivery. Women with pulmonary hypertension who received specialized care had excellent outcomes, with 100% survival for mothers and infants.
Researchers find a gene on the Y chromosome that may explain lower risk of pulmonary hypertension in men
Researchers at UCLA have identified a gene on the Y chromosome that protects against pulmonary hypertension in men by reducing proinflammatory chemokines. The study suggests that targeting inflammation may be a promising new avenue for therapy, and could lead to effective treatments for this fatal disease.
A CNIC study highlights the risks of mitochondrial therapeutic interventions
A new CNIC study warns that mitochondrial therapeutic interventions can cause damage due to the mixing of mitochondrial DNAs from two distinct origins. This can lead to medium- and long-term health issues, including heart failure, pulmonary hypertension, and muscle loss.
Gene that aids cancer cell proliferation is new target for deadly pulmonary hypertension
Scientists have found that the gene PBK is overexpressed in pulmonary hypertension, causing excessive cell proliferation and thickening of pulmonary artery walls. They are now exploring PBK inhibitors to reduce cell proliferation and improve heart and lung function.
Cleveland Clinic research identifies sildenafil as candidate drug for Alzheimer’s disease
The study, published in Nature Aging, found that sildenafil reduces the likelihood of developing Alzheimer's disease by 69% compared to non-users. Sildenafil also shows promise in treating the disease by increasing brain cell growth and decreasing hyperphosphorylation of tau proteins.
Novel computational pipeline could help repurpose cancer drugs for rare diseases
Researchers at University of Pittsburgh and Prairie View A&M University developed an algorithm to repurpose cancer drugs for pulmonary hypertension, a devastating lung disease. Two compounds improved human cells and rodent markers, supporting broader drug-repurposing platform use.
From 4500 possibilities, one compound emerges as promising treatment for PAH
A team of scientists at Stanford University and Cincinnati Children's have found a potentially effective compound, AG1296, to treat pulmonary arterial hypertension (PAH). The compound was identified using human, PAH-specific stem cells as a drug screening platform.
Pulmonary endarterectomy achieves excellent results for patients with segmental CTEPH
Patients with segmental CTEPH treated surgically achieved excellent outcomes, with 80% long-term survival and good quality of life. Multidisciplinary post-operative care is crucial for optimal results.
New virtual screening tool eases, accelerates routine diagnosis of pulmonary hypertension
The new virtual echocardiography screening tool (VEST) uses initial screening data from echocardiography to accurately diagnose pulmonary hypertension. VEST enables physicians to quickly evaluate patients for the condition by searching for routine key measures in echocardiogram reports, facilitating early recognition and timely treatment.
Treatment option improves chances of survival for babies with rare cerebrovascular disorder
A new treatment option shows promise in improving survival rates for babies with a rare cerebrovascular disorder. The study found that endovascular treatment can reduce the severity of pulmonary hypertension, allowing babies to cross the critical line on their way to survival.
Casting a wider net to catch more cases of pulmonary hypertension
Researchers from Brigham and Women's Hospital developed a new, lower threshold for pulmonary vascular resistance to diagnose patients at risk for death due to PH. The study found that 60% more patients can be diagnosed with PH using this new parameter.
LSU Health study suggests nicotine exposure alone leads to pulmonary hypertension
A new study from LSU Health reveals that chronic nicotine inhalation increases blood pressure and leads to pulmonary hypertension, accompanied by changes in lung and heart blood vessels. The researchers also found the adverse effects of inhaled nicotine are largely isolated to the right heart.
Respiratory diseases linked with high blood pressure in lungs
Pulmonary hypertension caused by respiratory disease has been linked to improved health outcomes through identifying underlying conditions. Researchers at the University of Missouri have found that thorough evaluations and tailored therapy approaches can help dogs with pulmonary hypertension, increasing survival rates.
Inflammation triggers silent mutation to cause deadly lung disease, Stanford study shows
Researchers at Stanford University School of Medicine have found that inflammation in the lungs can wake up a silent genetic defect that causes sudden onset cases of pulmonary hypertension. The study suggests that limiting potential environmental causes of lung inflammation may help prevent the development of the disease.
Cardiac MRI may lead to targeted PAH therapy
Researchers developed a cardiac MRI method to predict mortality risk in PAH patients. By monitoring right ventricular function, doctors can provide targeted therapies and measure their effectiveness.
ATS publishes new clinical guideline on home oxygen for children
The American Thoracic Society has developed a new clinical practice guideline for home oxygen therapy in children with chronic hypoxemia. The guideline makes specific recommendations for treating various respiratory and pulmonary conditions, such as cystic fibrosis, bronchopulmonary dysplasia, and interstitial lung disease.
Protein central to immune system function new target for treating pulmonary hypertension
Researchers have identified Toll-like receptor 3 as a new target for treating pulmonary hypertension by increasing its levels through high-dose RNA stimulation, potentially reducing inflammation and cell death in the lungs.
New pulmonary hypertension treatment target in the bull's-eye
Researchers have identified PFKFB3 as a key player in the development of pulmonary hypertension, a condition characterized by high blood pressure in the lungs. By targeting this enzyme, scientists hope to develop new treatments that can help alleviate symptoms and improve patient outcomes.
Study identifies new target for treatment of pulmonary hypertension
Researchers have identified FoxM1 as a potential target for treating pulmonary hypertension, a severe lung disease with a 50% five-year survival rate. Deleting the FoxM1 gene in mice resulted in thinner artery walls and improved right heart function.
Johns Hopkins investigators unravel biological roots of pulmonary hypertension
Scientists at Johns Hopkins Medicine have made significant breakthroughs in understanding the underlying biology behind pulmonary hypertension. By studying endothelial cells, they discovered that KLF15 protects these cells from damage caused by low oxygen levels, which can lead to blood vessel damage and progression of the disease.
Lung cancer triggers pulmonary hypertension
A study published in Science Translational Medicine found that lung cancer often leads to pulmonary hypertension due to immune cell activation and inflammatory processes triggered by cancer cells. This discovery could lead to new therapeutic approaches for developing a treatment.
Sildenafil should be avoided in valve disease with residual pulmonary hypertension
A study found that sildenafil increased the risk of hospitalization and death in patients with valvular heart disease and residual pulmonary hypertension. The drug should be avoided in these cases.
Evidence review supports pediatric use of PDE-5 inhibitors for pulmonary hypertension
A systematic review of PDE-5 inhibitor use in pediatric patients with pulmonary hypertension found improvements in oxygenation, hemodynamics, and clinical outcomes. The evidence suggests that low- and moderate-dose sildenafil are safe regimens for children, outweighing the risks associated with long-term use.